Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Monsanto Co. -- Ignore unavailable to you. Want to Upgrade?

To: David Winkler who wrote (848)	1/8/1999 1:03:00 PM
From: coyote	Read Replies (1) \| Respond to of 2539

insurers would be comparing to generic naproxen which would be closer to .24 per day

To: David Winkler who wrote (848)	1/8/1999 1:05:00 PM
From: Dan Spillane	Respond to of 2539

Monsanto has rattled the pain-relief drug industry in a big way! By pricing Celebrex at the same level as competing drugs, it is now likely they will capture more of the market, and faster. This will cause serious damage to almost every other drug maker. The irony here is that one of the reasons they priced this way is they didn't initially get the best Celebrex label (even thought the FDA states the drug is safer, but wants more time to change the label) -- DUE in large part to the lobbying efforts of competing drug makers! So those other drug companies are being hurt all the worse since now they are likely to lose market share all the faster. I agree all the talk about generic drugs doesn't make sense. There are no doubt interests of the other drug companies at work in those news items. The bottom line is the industry has been shaken up. The FDA has stated this drug is safer (despite the label, which is likely temporary), and now because of the pricing Celebrex is likely to capture even more market than originally anticipated.

To: David Winkler who wrote (848)	1/8/1999 10:08:00 PM
From: Anthony Wong	Read Replies (1) \| Respond to of 2539

ADVISORY/Kaiser Permanente in California has Made No Decision On Celebrex --(BW HealthWire)-- A New York Times story Friday speculates that Kaiser Permanente's California Division is considering not covering the newly approved arthritis drug Celebrex. This is only the newspaper's speculation, not a reflection of Kaiser Permanente's position. The Food and Drug Administration only last week approved the drug, noted Media Relations Director Tom Debley. The process of formulary review is just beginning. At least two physician formulary committees, one in Southern California and one in Northern California, must review a new drug before decisions can be made on a statewide basis. No decision has been made. ''To speculate on the outcome only a few days into a complex, perhaps months-long process, is pure conjecture,'' Debley said. News organizations considering reporting the New York Times' conclusion should read the entire story. There is no statement from Kaiser Permanente's physician to support the story's conjecture that ''Kaiser Permanente of California is considering not covering Celebrex at all.'' Contact: Kaiser Permanente News Bureau Tom Debley, Lila Petersen or Ann Mosher, 510/987-3900 biz.yahoo.com